Compare FNB & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | KOD |
|---|---|---|
| Founded | 1864 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 2002 | 2018 |
| Metric | FNB | KOD |
|---|---|---|
| Price | $18.43 | $97.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $20.33 | ★ $121.67 |
| AVG Volume (30 Days) | ★ 5.7M | 1.3M |
| Earning Date | 10-19-2026 | 11-16-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 22.83 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | $22.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.21 | $15.83 |
| 52 Week High | $19.59 | $104.00 |
| Indicator | FNB | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 63.68 |
| Support Level | $17.87 | $81.11 |
| Resistance Level | $18.89 | $103.63 |
| Average True Range (ATR) | 0.37 | 6.38 |
| MACD | 0.12 | -0.88 |
| Stochastic Oscillator | 92.18 | 73.28 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments, and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management, and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.